Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Diabetes, obesity & metabolism
- Publicado em
- 14 out 2025
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study
Weijun Gu, Xiaohong Wu, Minlu Zhang, Xinyi Wang, Qin Du, Lei Kang, Felipe Lauand, Agustina Alvarez, Yiming Mu
Descritores MeSH
- Insulin-Secreting Cells
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Insulin, Long-Acting
- Insulin Aspart
- Peptides
- Insulin Glargine
- C-Peptide
- Blood Glucose
- East Asian People
Veja também
Estudos relacionados
- Eficácia e Segurança do iGlarLixi versus IDegAsp por Idade basal, Duração da Doença e HbA1c em chineses com Diabetes Tipo 2: Análises Pós-Hoc do Estudo Soli-D
- The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial
- Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study